Angiogenesis and the ET-1/ETA receptor system: Immunohistochemical expression analysis in bone metastases from patients with different primary tumors

Angiogenesis

Volumn 6, Issue 3, 2003, Pages 225-231

  Medinger, Michael ^a   Adler, C P ^a   Schmidt Gersbach, C ^a   Soltau, J ^a   Droll, A ^a   Unger, C ^a   Drevs, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Angiogenesis; Bone metastases; Endothelin; Microvessel density; Vascular endothelial growth factor

Indexed keywords

CD31 ANTIGEN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL; BONE METASTASIS; BONE TISSUE; BONE TUMOR; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROENVIRONMENT; MICROVASCULATURE; PRIORITY JOURNAL; TUMOR CELL;

BONE NEOPLASMS; CASE-CONTROL STUDIES; ENDOTHELIN-1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ENDOTHELIN A; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 1942471854     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:AGEN.0000021395.43438.44     Document Type: Article

References (27)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Folkman J. Angiogenesis-dependent diseases. Semin Oncol 2001; 28: 536-42.
3. Folkman J. Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg 1972; 175: 409-16.
4. Medinger M, Drevs J. Anti-Angiogenese gegen Krebs: VEGF-Inhibitoren in der klinischen Prüfung. [Anti-angiogenesis against cancer: VEGF inhibitors in clinical trials.] Dtsch Apoth Ztg 2003; 143: 52-62.
5. Drevs J, Medinger M, Schmidt-Gersbach C et al. Receptor tyrosine kinases: The main targets for new anticancer therapy. Curr Drug Targets 2003; 4: 113-21.
6. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996; 271: 603-6.
7. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
8. Rubanyi GM, Polokoff MA. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994; 46: 325-415.
9. Bagnato A, Salani D, Di Castro V et al. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: Evidence for an autocrine role in tumor growth. Cancer Res 1999; 59: 720-7.
10. Baley PA, Resink TJ, Eppenberger U, Hahn AW. Endothelin messenger RNA and receptors are differentially expressed in cultured human breast epithelial and stromal cells. J Clin Invest 1990; 85: 1320-3.
11. Bagnato A, Cirilli A, Salani D et al. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res 2002; 62: 6381-4.
12. Nelson JB, Hedican SP, George DJ et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1: 944-9.
13. Takuwa Y, Masaki T, Yamashita K. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem Biophys Res Commun 1990; 170: 998-1005.
14. Kozawa O, Kawamura H, Hatakeyama D et al. Endothelin-1 induces vascular endothelial growth factor synthesis in osteoblasts: Involvement of p38 mitogen-activated protein kinase. Cell Signal 2000; 12: 375-80.
15. Carducci MA, Nelson JB, Bowling MK et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety and pharmacokinetics. J Clin Oncol 2002; 20: 2171-80.
16. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 2002; 14: 44-50.
17. Miki T, Yano S, Hanibuchi M, Sone S. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice. Oncol Res 2000; 12: 209-17.
18. Corey E, Quinn JE, Bladou F et al. Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 2002; 52: 20-33.
19. Iguchi H, Yokota M, Fukutomi M et al. A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 2002; 21: 309-13.
20. Holleb AI, Folkman J. Tumor angiogenesis. CA Cancer J Clin 1972; 22: 226-9.
21. Nakagawa M, Kaneda T, Arakawa T et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000; 473: 161-4.
22. Sweeney P, Karashima T, Kim SJ et al. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 2002; 8: 2714-24.
23. Kopetz ES, Nelson JB, Carducci MA. Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest New Drugs 2002; 20: 173-82.
24. Nelson JB, Nguyen SH, Wu-Wong JR et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 1999; 53: 1063-9.
25. Drevs J, Hofmann I, Hugenschmidt H et al. Effects of PTK787/ZK222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60: 4819-24.
26. Spinella F, Rosano L, Di Castro V et al. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1 alpha in ovarian carcinoma cells. J Biol Chem 2002; 277: 27850-5.
27. Rai A, Gulati A. Evidence for the involvement of ET(B) receptors in ET-1-induced changes in blood flow to the rat breast tumor. Cancer Chemother Pharmacol 2003; 51: 21-8.